RxDoctor Payments Data

Gordon Mortensen, MD

Pain Medicine · Milwaukee, WINPI 1407830862

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Boston Scientific at 41.2% of the total. Reporting peaked in 2020 at $8,851 and has fallen 91.7% since, to $733 in 2024.

$16,527in general payments, 2019–2025

Across 201 payments — averaging $82.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$7K
  • Medtronic$6K
  • Abbott$1K
  • Nevro Corp.$770
  • Collegium Pharmaceutical, Inc.$383
  • Tersera Therapeutics LLC$354
  • plus $2K from 26 others
$410in research payments, 2019–2025

Across 1 payment — averaging $410.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$410

What the payments were for

  • Speaking & faculty fees$9,35057%
  • Travel & lodging$2872%
  • Food & beverage$6,89042%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,527 in reported general payments places this provider in the 85th percentile of 82 pain medicine providers in Wisconsin.

See all pain medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$48,805
Medicare patients
133
Services billed
471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen281$10,868
Xtampza ErOxycodone Myristate14$8,917
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen212$5,058
BelbucaBuprenorphine Hcl12$4,913
Gabapentin202$2,899
Tizanidine Hcl111$1,903
Pregabalin65$1,899
Morphine Sulfate ErMorphine Sulfate51$1,457
Lidocaine15$1,154
Fentanyl11$745
Methadone Hcl37$654
Baclofen46$609
Hydromorphone Hcl25$493
Tramadol Hcl62$448
Zonisamide20$410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$383$13,83126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 82 pain medicine providers in Wisconsin.

Other pain medicine in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →